Menu
Close
About Us
Company Overview
Our History
Leadership
Board of Directors
Our Advisors
Therapeutic Areas
COVID-19 and CVD
Acute Myocarditis
Heart Failure
Research
R&D Partners
Our Science
Resources
Pipeline
CardiolRX™
Investors
Events & Presentations
Press Releases
Analyst Coverage
Stock Information
Filings & Financials
Corporate Governance
Contact Us
News
Cardiol Therapeutics to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
September 15, 2020
Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx™
August 26, 2020
Cardiol Therapeutics Appoints CNBC Market Analyst Steven Grasso as Business Advisor
June 29, 2020
David Elsley Files Early Warning Report for Cardiol Therapeutics
June 25, 2020
Cardiol Therapeutics Closes $17.25 Million Bought Deal Offering, Including Full Exercise of the Over-Allotment Option
June 04, 2020
Cardiol Therapeutics Reports 2020 AGM Results
June 02, 2020
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 1st at 4:30 p.m. EDT
May 29, 2020
Cardiol Therapeutics Announces Increase to Previously Announced Bought Deal Public Offering
May 14, 2020
Cardiol Therapeutics Announces $11.25 Million Bought Deal Public Offering
May 13, 2020
Cardiol Therapeutics Files International Patent Application Covering the Use of Cannabidiol (CBD) to Improve the Outcome of Patients with COVID-19
May 06, 2020
Page 2 of 7
«
1
2
3
4
5
...
»
Last »
